Vivoryon Therapeutics N.V. Shares Highlights from Virtual R&D Update with KOL Speakers
February 19, 2025 12:00 ET
|
Vivoryon Therapeutics N.V.
Vivoryon Therapeutics N.V. Shares Highlights from Virtual R&D Update with KOL Speakers Halle (Saale) / Munich, Germany, February 19, 2025 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY;...
Vivoryon Therapeutics N.V. to Host Virtual R&D Update with KOL Speakers on February 18, 2025
February 11, 2025 12:00 ET
|
Vivoryon Therapeutics N.V.
Vivoryon Therapeutics N.V. to Host Virtual R&D Update with KOL Speakers on February 18, 2025 Halle (Saale) / Munich, Germany, February 11, 2025 - Vivoryon Therapeutics N.V. (Euronext Amsterdam:...
Vivoryon Therapeutics N.V. Provides R&D-Update Further Strengthening Development Pipeline in Kidney Disease
January 14, 2025 01:00 ET
|
Vivoryon Therapeutics N.V.
Vivoryon Therapeutics N.V. Provides R&D-Update Further Strengthening Development Pipeline in Kidney Disease A meta-analysis of VIVIAD and VIVA-MIND1 data confirmed that treatment with...
Vivoryon Therapeutics N.V. Reports Q3 2024 Results and Highlights Progress on Varoglutamstat in Kidney Disease
December 10, 2024 01:00 ET
|
Vivoryon Therapeutics N.V.
Vivoryon Therapeutics N.V. Reports Q3 2024 Results and Highlights Progress on Varoglutamstat in Kidney Disease Varoglutamstat Phase 2 program shows highly consistent, statistically significant and...
Vivoryon Therapeutics N.V. Presents Topline Phase 2 Data from VIVA-MIND Strongly Supporting Varoglutamstat’s Potential to Improve Kidney Function
December 09, 2024 01:00 ET
|
Vivoryon Therapeutics N.V.
Vivoryon Therapeutics N.V. Presents Topline Phase 2 Data fromVIVA-MIND Strongly Supporting Varoglutamstat’s Potential toImprove Kidney FunctionVIVA-MIND Phase 2 data confirm results of...
Vivoryon Therapeutics N.V. to Report Q3 2024 Financial Results and Operational Progress on December 10, 2024
December 04, 2024 01:00 ET
|
Vivoryon Therapeutics N.V.
Vivoryon Therapeutics N.V. to Report Q3 2024 Financial Results and Operational Progress on December 10, 2024 Halle (Saale) / Munich, Germany, December 04, 2024 - Vivoryon Therapeutics N.V....
Vivoryon Therapeutics N.V. Presents Outstanding Phase 2b Results of Varoglutamstat on Kidney Function at ASN Kidney Week 2024
October 26, 2024 03:30 ET
|
Vivoryon Therapeutics N.V.
Vivoryon Therapeutics N.V. Presents Outstanding Phase 2b Results of Varoglutamstat on Kidney Function at ASN Kidney Week 2024 Selected for late-breaking oral presentation at ASN kidney week, the...
Vivoryon Therapeutics N.V. Announces Late-breaking Oral Presentation at the American Society of Nephrology Kidney Week 2024
October 11, 2024 09:20 ET
|
Vivoryon Therapeutics N.V.
Halle (Saale) / Munich, Germany, October 11, 2024 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on the discovery and development of...
Vivoryon Therapeutics N.V. Shares Highlights from Virtual Kidney Disease KOL Event
October 01, 2024 01:00 ET
|
Vivoryon Therapeutics N.V.
Halle (Saale) / Munich, Germany, October 1, 2024 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on the discovery and development of...
Vivoryon Therapeutics N.V. Reports H1 2024 Progress Marked by Compelling Kidney Function Data and Execution of Strategy to Advance Varoglutamstat in Kidney Disease
September 12, 2024 01:00 ET
|
Vivoryon Therapeutics N.V.
Vivoryon Therapeutics N.V. Reports H1 2024 Progress Marked by Compelling Kidney Function Data and Execution of Strategy to Advance Varoglutamstat in Kidney Disease Primary focus is developing...